Related Experiment Video

Updated: May 10, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Potassium channel activation inhibits proliferation of breast cancer cells by activating a senescence program

K Lansu1, S Gentile

  • 1Molecular Pharmacology and Therapeutics, Loyola University, Chicago, IL, USA.

Cell Death & Disease
|June 8, 2013
PubMed

Insights

Activating the hERG1 potassium channel with NS1643 halts cancer cell growth and triggers senescence. This discovery offers a novel therapeutic strategy for inhibiting cancer proliferation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cardiovascular Physiology

Background:

  • The hERG1 potassium channel is crucial for cardiac myocyte excitability.
  • hERG1 expression in non-excitable cancer cells suggests a potential role in cancer biology.
  • Previous studies on hERG1 inhibition in breast cancer cells yielded conflicting results regarding apoptosis.

Purpose of the Study:

  • To investigate the effects of hERG1 hyperstimulation in human mammary gland adenocarcinoma cells.
  • To explore the potential of hERG1 activation as an antiproliferative cancer therapy.

Main Methods:

  • Treatment of cancer cells with the hERG1 activator NS1643 (a diphenylurea derivative).
  • Cell cycle analysis to determine cell cycle arrest.
  • Assessment of apoptosis markers.
  • Evaluation of senescence markers, including p21, p16(INK4a) protein levels, and β-galactosidase activity.

Main Results:

  • NS1643 irreversibly inhibited cancer cell proliferation.
  • Cell cycle arrest occurred preferentially in the G0/G1 phase without inducing apoptosis.
  • Cells exhibited a senescence-like phenotype, characterized by increased p21 and p16(INK4a) levels and a positive β-galactosidase assay.

Conclusions:

  • Prolonged stimulation of the hERG1 potassium channel can induce a senescence program in cancer cells.
  • hERG1 channel activation presents a promising therapeutic strategy for antiproliferative cancer treatment.

More Related Videos

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...